Shares of Novavax, Inc. (NVAX) are up almost 4% to $4.50 in pre-market trading Wednesday after the company was initiated with a ‘Buy’ rating at Citigroup (C). Currently there are 2 analysts that rate Novavax shares a ‘Strong Buy’ and 2 a ‘Buy’. No analysts rate it a ‘Sell’. The biopharmaceuticals company has a median […] View the full post at: Novavax, Inc. (NVAX) Initiated with a Buy at Citigroup Related posts: Citigroup Scores